PROCEPT BioRobotics Past Earnings Performance
Past criteria checks 0/6
PROCEPT BioRobotics's earnings have been declining at an average annual rate of -16.5%, while the Medical Equipment industry saw earnings growing at 14.9% annually. Revenues have been growing at an average rate of 53.8% per year.
Key information
-16.47%
Earnings growth rate
56.13%
EPS growth rate
| Medical Equipment Industry Growth | 8.90% |
| Revenue growth rate | 53.83% |
| Return on equity | -23.18% |
| Net Margin | -36.20% |
| Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
PROCEPT BioRobotics: A 'Razor And Razor Blade' Business Model
May 19US$77.00: That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After Its Latest Results
Apr 27
Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects
Apr 18
HYDROS Robotic System Launch And Aquablation Trials Will Drive Future Market Expansion
Launch of HYDROS Robotic System and FDA approvals likely to increase procedural adoption and drive revenue growth.Procept BioRobotics: Strong Growth, But Profitability Seems Far Away
Mar 11PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$93.86 Price Target
Feb 28What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S
Dec 05Procept BioRobotics: Continued Growth Runway Ahead
Nov 26Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102
Oct 31Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth
Sep 12Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval
Aug 27Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%
Aug 25Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results
Aug 04PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce
May 21The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Apr 05US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results
Mar 01Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt
Feb 07Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher
Dec 14Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?
Feb 27Revenue & Expenses Breakdown
How PROCEPT BioRobotics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 25 | 249 | -90 | 187 | 66 |
| 31 Dec 24 | 224 | -91 | 171 | 62 |
| 30 Sep 24 | 200 | -100 | 159 | 62 |
| 30 Jun 24 | 177 | -104 | 150 | 57 |
| 31 Mar 24 | 156 | -103 | 141 | 51 |
| 31 Dec 23 | 136 | -106 | 132 | 48 |
| 30 Sep 23 | 116 | -107 | 121 | 44 |
| 30 Jun 23 | 102 | -105 | 113 | 40 |
| 31 Mar 23 | 85 | -98 | 101 | 35 |
| 31 Dec 22 | 75 | -87 | 89 | 29 |
| 30 Sep 22 | 61 | -77 | 79 | 24 |
| 30 Jun 22 | 50 | -69 | 66 | 22 |
| 31 Mar 22 | 41 | -64 | 59 | 19 |
| 31 Dec 21 | 34 | -60 | 51 | 19 |
| 30 Sep 21 | 28 | -57 | 44 | 18 |
| 30 Jun 21 | 21 | -55 | 39 | 17 |
| 31 Mar 21 | 14 | -53 | 34 | 17 |
| 31 Dec 20 | 8 | -53 | 30 | 16 |
| 31 Dec 19 | 6 | -42 | 29 | 13 |
Quality Earnings: PRCT is currently unprofitable.
Growing Profit Margin: PRCT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRCT is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.
Accelerating Growth: Unable to compare PRCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRCT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15.5%).
Return on Equity
High ROE: PRCT has a negative Return on Equity (-23.18%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/28 13:56 |
| End of Day Share Price | 2025/05/28 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PROCEPT BioRobotics Corporation is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Craig Bijou | BofA Global Research |
| Neil Chatterji | B. Riley Securities, Inc. |
| Michael Gorman | BTIG |